NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs

Current Opinion in Investigational Drugs

Volumn 9, Issue 11, 2008, Pages 1151-1156

  Wallace, J L ^a   Vong, L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Arthritis; Hydrogen sulfide; Inflammation; Nitric oxide; Prostaglandin; Ulcer

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACS 15; ATB 337; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; HYDROGEN SULFIDE; LUMIRACOXIB; NAPROXEN; NITRIC OXIDE; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIZZINESS; DRUG DESIGN; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE ULCER; KIDNEY INJURY; MEDIATOR RELEASE; NONHUMAN; PATHOGENESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; STOMACH ULCER; STROKE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; GASTROINTESTINAL TRACT; HUMANS; HYDROGEN SULFIDE; NITRIC OXIDE; PROSTAGLANDIN ANTAGONISTS;

EID: 54949089316     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med (1999) 340(24):1888-1899.
2. Wallace JL, Tigley AW: Review article: New insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther (1995) 9(3):227-235.
3. Davies NM, Sharkey KA, Asfaha S, MacNaughton WK, Wallace JL: Aspirin causes rapid up-regulation of cyclooxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther (1997) 11(6):1101-1108. • The first demonstration of rapid upregulation of COX-2 in the stomach after exposure of the mucosa to an agent that suppresses COX-1. This suggested that the upregulation of COX-2 was a compensatory response to diminished mucosal PG levels.
4. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM: Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol (1999) 128(8):1659-1666.
5. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology (1997) 112(2):387-397. • This was the first paper to report that COX-2 was strongly induced along the margins of gastric ulcers, and selective inhibition of COX-2 led to a significant inhibition of ulcer healing.
6. Wallace JL, Devchand PR: Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol (2005) 145(3):275-282.
7. Ma L, del Soldato P, Wallace JL: Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci USA (2002) 99(20):13243-13247.
8. Wallace JL, McKnight W, Reuter BK, Vergnolle N: NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology (2000) 119(3):706-714. • A demonstration that selective inhibition of either COX isoform alone is insufficient to induce gastric damage. This paper highlighted an important contribution of COX-2 to mucosal defense in the healthy GI tract.
9. Kakuta H, Zheng X, Oda H, Harada S, Sugimoto Y, Sasaki K, Tai A: Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J Med Chem (2008) 51(8):2400-2411.
10. Hippisley-Cox J, Coupland C, Logan R: Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: Population based nested case-control analysis. Br Med J (2005) 331(7528):1310-1316.
11. Lanas A, Baron JA, Sandler RS, Horgan K, Bolognese J, Oxenius B, Quan H, Watson D, Cook TJ, Schoen R, Burke C et al: Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology (2007) 132(2):490-497. •• This paper provided evidence that a selective COX-2 inhibitor, rofecoxib, produced significantly more ulcers and bleeding than placebo, which contradicted earlier claims about the GI safety of rofecoxib.
12. Wallace JL: Selective COX-2 inhibitors: Is the water becoming muddy? Trends Pharmacol Sci (1999) 20(1):4-6.
13. Wallace JL: The 1994 Merck Frosst Award. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage - potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol (1994) 72(12):1493-1498.
14. Muscará MN, Vergnolle N, Lovren F, Triggle CR, Elliott SN, Asfaha S, Wallace JL: Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol (2000) 129(7):1423-1430.
15. Abraham NS, El-Serag HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 selectivity of non-steroidal antiinflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther (2007) 25(8):913-924.
16. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL et al: Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation (2008) 117(16):2104-2113.
17. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J (2006) 332(7553):1302-1308. •• This analysis of cardiovascular events among NSAID users strongly suggested that all NSAIDs, not just selective COX-2 inhibitors, had the capacity to increase the incidence of serious cardiovascular events (naproxen being a possible exception).
18. Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest (2006) 116(1):4-15.
19. Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD: Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J (2006) 20(14):2468-2475. •• This provocative and elegant study provided evidence to support the theory that NSAIDs may affect COX-1 activity differently in the endothelium compared with platelets and this may underlie the ability of NSAIDs to increase the incidence of serious cardiovascular events.
20. Warner TD, Mitchell JA: COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet (2008) 371(9608):270-273.
21. Fitzgerald GA: Coxibs and cardiovascular disease. N Eng J Med (2004) 351(17):1709-1711.
22. Samuelsson B, Morgenstern R, Jakobsson PJ: Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev (2007) 59(3):207-224.
23. 2 synthases. Clin Immunol (2006) 119(3):229-240.
24. 2 production in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol (2005) 288(2):G308-G315. • This paper reports data suggesting that PG derived from mPGES-1 may play an important role in ulcer healing. This highlights the importance of examining the safety of selective inhibitors of mPGES-1 in animal models of ulcer healing.
25. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, FitzGerald GA: Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest (2006) 116(5):1391-1399.
26. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A et al: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 388(6643):678-682.
27. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL: Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA (2001) 98(11):6470-6475.
28. Miura S, Tatsuguchi A, Wada K, Takeyama H, Shinji Y, Hiratsuka T, Futagami S, Miyake K, Gudis K, Mizokami Y, Matsuoka T et al: Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. Am J Physiol Gastrointest Liver Physiol (2004) 287(2):G444-G451.
29. 2 accelerates the healing of gastric ulcers via EP4 receptors. Am J Physiol Gastrointest Liver Physiol (2007) 293(4):G788-G797.
30. Wallace JL: Building a better aspirin: Gaseous solutions to a century-old problem. Br J Pharmacol (2007) 152(4):421-428.
31. Konturek SJ, Brzozowski T, Majka J, Pytko-Poloncyzk J, Stachura J: Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol (1993) 239(1-3):215-217.
32. Elliott SN, McKnight W, Cirino G, Wallace JL: A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in the rat. Gastroenterology (1995) 109(2):524-530.
33. Fiorucci S, Antonelli E, Distrutti E, Mencarelli A, Orlandi S, Zanardo R, Renga B, Rizzo G, Morelli A, Cirino G, Wallace JL: Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 129(4):1210-1224.
34. MacNaughton WK, Cirino G, Wallace JL: Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci (1989) 45(20):1869-1876.
35. Wallace JL, Dicay M, McKnight W, Martin GR: Hydrogen sulfide enhances ulcer healing. FASEB J (2007) 21(14):4070-4076.
36. Miller MJS, Wallace JL: Nitric oxide and mucosal defence: A little goes a long way. Gastroenterology (2000) 119(2):512-520.
37. 2S tonically downregulates inflammatory processes.
38. Wallace JL, Del Soldato P: The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol (2003) 17(1):11-20.
39. Wilder-Smith CH, Jonzon B, Fornstedt-Wallin B, Hedman A, Karlsson P: Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scand J Gastroenterol (2006) 41(3):264-273.
40. Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A: Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum (2005) 53(6):827-837. • First clinical evidence that an NO-releasing NSAID derivative could reduce the symptoms of osteoarthritis at least as effectively as the parent NSAID (naproxen) and a selective COX-2 inhibitor (rofecoxib).
41. NicOx SA: NicOx completes patient enrollment in third naproxcinod pivotal phase 3 study. Press Release (2008): May 28.
42. Muscará MN, McKnight W, Lovren F, Triggle CR, Cirino G, Wallace JL: Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol (2000) 279(2):H528-H535.
43. Michael Hill C, Sindet-Pederson S, Seymour RA, Hawkesford JE 2nd, Coulthard P, Lamey PJ, Gerry Cowan C, Wickens M, Jeppsson L, Dean AD, Svensson O: Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. Clin Ther (2006) 28(9):1279-1295.
44. Fiorucci S, Distrutti E, Cirino G, Wallace JL: The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 131(1):259-271.
45. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S: Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat. Gastroenterology (2007) 132(1):261-271.
46. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK: Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Rad Biol Med (2007) 42(5):706-719.
47. ATP channels. J Pharmacol Exp Ther (2006) 316(1):325-335.
48. 2S-releasing diclofenac protects mice against acute pancreatitis-associated lung injury. Shock (2008) 29(1):84-88.
49. Rossoni G, Manfredi B, Del Soldato P, Berti F: The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J Pharmacol Exp Ther (2004) 310(2):555-562.
50. Rossoni G, Sparatore A, Tazzari V, Manfredi B, Del Soldato P, Berti F: The hydrogen sulphide-releasing derivative of diclofenac protects against ischaemia-reperfusion injury in the isolated rabbit heart. Br J Pharmacol (2008) 153(1):100-109.
51. Rossoni G, Muscara MN, Cirino G, Wallace JL: Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol (2002) 135(6):1540-1546.